on BioVersys AG
BioVersys to Host Virtual Event on BV100 Study for VABP
BioVersys AG, a Swiss clinical stage biopharmaceutical company, announced a virtual key opinion leader event scheduled for May 7, 2025. The focus will be on the Phase 2 study of BV100, aimed at treating ventilator-associated pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii. The event will feature Professor David Paterson from the National University of Singapore and Dr. Andrew Shorr of Medstar Washington Hospital Center.
BV100 is an innovative formulation of rifabutin with a new mechanism of action for intravenous use, showing significant survival benefits in clinical trials. The event will discuss unmet needs and the current treatment landscape for this resistant bacteria. After formal presentations, a live Q&A session will take place.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioVersys AG news